Finch Norman D. Jr. 4

What Happened

• Norman D. Finch Jr., SVP, General Counsel & Corporate Secretary of West Pharmaceutical Services, was awarded a total of 4,342 restricted stock units (RSUs) on March 1, 2026 (two awards: 1,285 RSUs and 3,057 RSUs). Each award was granted at $0.00 (derivative award); the grant represents a contingent right to receive shares in the future rather than an immediate purchase of stock.

Key Details

• Transaction date: 2026-03-01 (reported on Form 4 filed 2026-03-03).
• Transaction type/code: A = Award/Grant (RSUs); quantities 1,285 and 3,057; grant price $0.00.
• Total RSUs granted: 4,342.
• Shares owned after transaction: not provided in the supplied filing excerpt.
• Footnotes: F1 — each RSU represents a contingent right to one share; F2 — these RSUs vest in four equal annual installments beginning March 1, 2027; F3 — notes stock option vesting (four equal annual installments beginning March 1, 2027) if applicable.
• Filing timeliness: Reported on March 3, 2026 for a March 1, 2026 transaction — appears timely (Form 4s are typically due within two business days).

Context

• RSU grants are compensation/retention awards, not an open-market purchase or sale; they do not represent immediate share ownership until vested and settled. These awards vest over four years (starting 3/1/2027), so any potential impact on share count or insider selling would occur later as vesting and any elections (e.g., withholding) are executed.